This is consistent with our observation that pharmacological or genetic knockdown of NRF2 reduces both HER4 and pAkt levels, and pharmacological activation of NRF2 induces both HER4 and pAkt and confers protection and survival of cancer cells following LAP and/or ERL treatments. This evidence concerns the gene CEBPB and cancer.